1. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (June 2017) Authors: Casasnovas, R.; Westin, J.; Thieblemont, C.; Zijlstra, J.; Hill, B.; De La Cruz Vicente, F.; Choquet, S.; Caimi, P.; Kaplan, J.; Canales, M.; Kuruvilla, J.; Follows, G.; van den Neste, E.; Meade, J.; Wrigley, B.; Devlin, M.; Saint‐Martin, J.; Nippgen, C.; Gardner, H.; Shacham, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Kalakonda, N.; Cavallo, F.; Follows, G.; Goy, A.; Vermaat, J.; Casasnovas, O.; Lavee, O.; Maerevoet, M.; Zijlstra, J.; Bakshi, S.; Bouabdallah, R.; Choquet, S.; Gurion, R.; Hill, B.; Jaeger, U.; Sancho, J.; Schuster, M.; Thieblemont, C.; De la Cruz, F.; Egyed, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Advanced Hodgkin lymphoma in the east of England cancer network: A 10‐year comparative analysis of outcomes for ABVD and escalated‐BEACOPP treated patients aged 16 to 59. (June 2017) Authors: Russell, J.; Collins, A.; Fowler, A.; Karanth, M.; Saha, C.; Shyamsundar, V.; Docherty, S.; Kirkwood, A.; Maw, K.; Cooke, L.; Hodson, A.; Shah, N.; Sadullah, S.; Grigoropoulos, N.; Uttenthal, B.; Follows, G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE / PROCARBAZINE SUBSTITUTION REDUCES RED CELL TRANSFUSION REQUIREMENTS AND MAY SHORTEN TIME TO MENSTRUAL PERIOD RECOVERY. (12th June 2019) Authors: Follows, G.; Santarsieri, A.; Sturgess, K.; Menne, T.; Osborne, W.; Creasey, T.; Ardeshna, K.M.; Behan, S.; Booth, S.; Collins, G.; Cwynarski, K.; Iyengar, S.; Jones, S.; Martinez‐Calle, N.; McKay, P.; Nagumantry, S.K.; O'Mahony, D.; Rudge, J.F.; Shah, N.; Stafford, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 490 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN. (23rd June 2022) Authors: Sharman, J. P.; Egyed, M.; Jurczak, W.; Skarbnik, A.; Patel, K.; Flinn, I. W.; Kamdar, M.; Munir, T.; Walewska, R.; Fogliatto, L. M.; Herishanu, Y.; Banerji, V.; Follows, G.; Walker, P.; Karlsson, K.; Ghia, P.; Janssens, A.; Cymbalista, F.; Ferrant, E.; Wierda, W. G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PO-0737: Is there a role for hippocampal sparing consolidation radiotherapy in primary CNS lymphoma (PCNSL)?. (April 2018) Authors: Buckley, H.; Follows, G.; Ajithkumar, T. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗